Inhibitor Therapeutics Inc Watch

from 10-K 30 pages Irs Employer Identification No. 30-0793665

from 8-K 5 pages Consulting Agreement

from 8-K 7 pages Inhibitor Therapeutics, Inc. Employment Agreement

from 8-K 9 pages Inhibitor Therapeutics, Inc. Employment Agreement

from 8-K 10 pages B Mayne Pharma and INTI Are Parties to a Certain Stipulation and Agreement of Compromise, Settlement and Release Dated as of September 9, 2022 Pending Approval by the Court of Chancery of the State of Delaware (The Stipulation), Pursuant to Which the 2018 Agreement Is to Be Voided as of the Effective Date (Defined) Except as Provided in the Stipulation, Including With Respect to the Licence to Mayne Pharma of Rights Arising Under Certain INTI Patents (Defined) and Inti’s Right to a 9% Cash Royalty on Future Net Sales, if Any, of the Product (Defined) in the United States and Mayne Pharma’s Right to Set Off Any Royalties Due to INTI on Future Net Sales of the Product Against Usd 3,000,000.00 Advance Paid to INTI Under the 2018 Agreement

from 8-K 45 pages In the Court of Chancery of the State of Delaware

from 10-Q 25 pages Redactions With Respect to Certain Portions Hereof Denoted With “***” Execution Date: August 27, 2019 Effective Date: August 20, 2019 Sublicense Agreement Between Mayne Pharma International Pty Ltd & Inhibitor Therapeutics, Inc. Sublicense Agreement

from 10-K 12 pages Agreement

from 10-K 25 pages Irs Employer Identification No. 30-0793665

from 10-K 59 pages Irs Employer Identification No. 30-0793665

from 8-K 6 pages Confidential via Email December 31 2018 Garrison J. Hasara, Cpa C/O Hedgepath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Garry

from 8-K 6 pages Confidential via Email December 31, 2018 Mr. Nicholas J. Virca C/O Hedgepath Pharmaceuticals, Inc. 324 S. Hyde Park Avenue, Suite 350 Tampa, Florida 33606 Re: Terms of Employment Dear Nick

from 8-K 11 pages Irs Employer Identification No. 30-0793665

from 8-K 40 pages Securities Purchase Agreement Dated January 8, 2018 by and Between Hedgepath Pharmaceuticals, Inc. and Mayne Pharma Ventures Pty Ltd

from 10-K 1 page Amendment No. 1 to Second Amended and Restated Supply and License Agreement

from 10-K 3 pages First Amendment to Employment Agreement

from 10-K 4 pages Second Amendment to Employment Agreement

from 8-K 37 pages Securities Purchase Agreement

from S-1/A 37 pages Securities Purchase Agreement

from 8-K 3 pages Amendment No. 1 to Amended and Restated Equity Holders’ Agreement